Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials: Comparison of SSRIs and SNRIs in major depressive disorder
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Context: Controversy exists whether serotonin–norepinephrine reuptake inhibitors (SNRIs) have improved efficacy compared with selective serotonin reuptake inhibitors (SSRIs). Objective: To compare clinical outcomes of adults treated with SSRIs or SNRIs for major depressive disorder (MDD) under ideal clinical condition, research design, and outcome measure. Data sources: Electronic databases searched were Medline, Embase and Cochrane Library from inception to July 2007. Study selection: Included studies were those head-to-head randomized trials comparing remission (HAMD-17 ≤7–8, MADRS ≤10–12) after 8–12 weeks of therapeutic doses of SSRIs or SNRIs in patients diagnosed with MDD were targeted for analysis. Reviews, letters, commentaries, economic studies, etc. were excluded. Studies were reviewed by two independent researchers. Where disagreements occurred in study selection, a consensus approach was used. Data extraction and analysis: Targeted outcome data included number of patients achieving remission, withdrawing from therapy due to lack of efficacy (LoE) and/or adverse drug reactions (ADRs), and total patients in trial. A random effects model combined intent-to-treat (ITT) and per-protocol (PP) odds ratio (OR), and remission and dropout rates. Chi-square assessed heterogeneity. Quality assessment was done using Downs-Black checklist. Results: Thirty-three studies were identified; 18 were rejected (patients had co-morbidities in 7, outcomes differed in 5, different follow-up in 3, and three reviews). Fifteen head-to-head trials of 3094 patients, average age was 41·9 ± 11·9 years (for SNRIs) and 41·6 ± 12·1 years (for SSRIs), P = 0·941. All analyses displayed non-heterogeneity (P > 0·05). The OR (under ITT) was 1·27 (1·06–1·52 95% CI) favoring SNRIs. Meta-analytic remission rates were 48·5 ± 3·2% and 41·9 ± 4·2% for SNRIs and SSRIs, respectively. The meta-analytic difference in remission rates between drugs was 5·7% (P = 0·007). Dropout rates due to ADRs were higher with SNRIs than SSRIs (3·2% difference, P < 0·001). Dropout rates due to LoE were non-significant between studied groups (P > 0·05). Conclusions: Serotonin and norepinephrine reuptake inhibitors showed statistical but not clinical significance when compared with SSRIs in treating MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“A more stringent measure of antidepressant efficacy is remission, which is a clinical state characterized by minimal residual symptoms (11).”
BackgroundDuloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 1×
“ITT Alves (1999) (45) 0Æ500 0Æ079 40 0Æ404 0Æ072 47 1Æ47 0Æ63 3Æ45 Ballus (2000) (29) 0Æ561 0Æ078 41 0Æ326 0Æ071 43 2Æ65 1Æ09 6Æ43 Bielsky (2004) (46) 0Æ420 0Æ049 100 0Æ505 0Æ051 97 0Æ71 0Æ40 1Æ24 Costa e Silva (1998) (47) 0Æ602 0Æ035 196 0Æ602 0Æ036 186 1Æ00 0Æ66 1Æ51 Detke (2004) (48) 0Æ505 0Æ052 93 0Æ471 0Æ054 85 1…”
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1046 · Cited by 252 · cited 1×
“However, the achievement of remission is of considerable clinical importance as it predicts decreased risk of relapse and greater psychosocial functioning than typically observed in patients who have achieved clinical response alone (13, 16, 17).”
BackgroundEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158 · cited 1×
“ITT Alves (1999) (45) 0Æ500 0Æ079 40 0Æ404 0Æ072 47 1Æ47 0Æ63 3Æ45 Ballus (2000) (29) 0Æ561 0Æ078 41 0Æ326 0Æ071 43 2Æ65 1Æ09 6Æ43 Bielsky (2004) (46) 0Æ420 0Æ049 100 0Æ505 0Æ051 97 0Æ71 0Æ40 1Æ24 Costa e Silva (1998) (47) 0Æ602 0Æ035 196 0Æ602 0Æ036 186 1Æ00 0Æ66 1Æ51 Detke (2004) (48) 0Æ505 0Æ052 93 0Æ471 0Æ054 85 1…”
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Esketamine combined with SSRI or SNRI for treatment-resistant depression
Del Casale, A., Spirito, S., Arena, J. F., Preissner, S., Borro, M., Gentile, G., Modesti, M. N., Preissner, R., Ferracuti, S., & Simmaco, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0200 · Cited by 23
Metadata
- Authors
- Machado, M., & Einarson, T. R.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2009-06-02
- Volume
- 35
- Issue
- 2
- Pages
- 177-188
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W2121484633
- Cited by
- 52
- References
- 13
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials: Comparison of SSRIs and SNRIs in major depressive disorder. https://app.cochat.ai/papers/10.1111/j.1365-2710.2009.01050.x
- The paper
- Machado, M., & Einarson, T. R. (2010). Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials: Comparison of SSRIs and SNRIs in major depressive disorder. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/j.1365-2710.2009.01050.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.